Abstract
In The Lancet Gastroenterology & Hepatology, Choong-kun Lee and colleagues1 report the results of a single-arm, phase 2 trial assessing folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and trastuzumab in patients with HER2-positive advanced biliary tract cancers pre-treated with gemcitabine and cisplatin (mostly as second-line treatment). As expected, the majority of patients had a gallbladder cancer (53%) or extrahepatic cholangiocarcinoma (29%). The trial met its primary endpoint, achieving an objective response rate of 29·4% (95% CI 16·7–46·3) that surpassed the planned 25%, and excluded the null hypothesis of 10%.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
